SC
AMLX icon

Stempoint Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Stempoint Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.9M Sell
384,304
-285,381
-43% -$4.41M 1.19% 27
2026
Q1 		$9.31M Buy
669,685
+104,545
+18% +$1.47M 1.78% 17
2025
Q4 		$6.83M Buy
565,140
+288,256
+104% +$3.92M 1.17% 25
2025
Q3 		$3.76M Buy
+276,884
New +$2.61M 0.75% 34
2024
Q1 		– Sell
-83,381
Closed -$1.23M – 65
2023
Q4 		$1.23M Buy
+83,381
New +$1.28M 0.33% 55

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Stempoint Capital's AMLX Position: Q2 2026 in Review

Stempoint Capital reduced its Amylyx Pharmaceuticals (AMLX) stake by 43% in Q2 2026, selling an estimated $4.41M and leaving 384,304 shares worth $6.9M. The position accounts for 1.19% of the portfolio, ranked #27.

Stempoint Capital first reported a position in AMLX in Q4 2023 and has held it in 5 quarters since. The position peaked at $9.31M in Q1 2026. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Stempoint Capital held 384,304 shares of Amylyx Pharmaceuticals worth $6.9M as of Q2 2026.
  • Stempoint Capital sold 285,381 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $4.41M.
  • Amylyx Pharmaceuticals made up 1.19% of Stempoint Capital's portfolio in Q2 2026, its #27 holding.
  • Stempoint Capital first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 5 quarters since.
  • Stempoint Capital's Amylyx Pharmaceuticals position peaked at $9.31M in Q1 2026.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.